Biocon Biologics partners with Sandoz for distribution of its biosimilar to treat immune-related diseases in Japan
时间:2024-06-26 06:31:53 阅读(143)
Biocon Biologics Ltd on Friday signed a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute th injection of Adalimumab BS in Japan.
“Based on this Agreement, Viatris has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024. Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate,” the company said in a statement.
“Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth,” it added.
The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz’s immunology and biosimilar portfolio.
Biocon Biologics recently announced the successful completion of its integration of the acquired Viatris’ biosimilars business in 120 countries ahead of schedule, marking a significant milestone in the Company’s journey as a fully integrated, global biosimilars enterprise. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, and ophthalmology.
猜你喜欢
- Xiaomi 14 series, iQOO 12 and more- All smartphones confirmed to rock Qualcomm Snapdragon 8 Gen 3 so far
- US Stocks- Wall St heads for mixed open as rate worries linger
- US Stocks- Wall St set for opening losses in gloomy start to second-half
- Nifty, Sensex surge 2% on strong global cues as bulls return to D-St; ‘market trend bullish, buy on dips’
- Year-ahead -Top realtors expect 10-15% jump in home sales
- US Stock-market Wrap-up- Wall Street rallies on back of big tech, banks; Dow up 2%
- Younion appoints Arindam Roychowdhury as vice president – strategic growth
- Nifty, Sensex soar nearly 3%, resistance at 16400; volatility to continue, focus to be on macro data
- YS Sharmila joins Congress, merges YSRTP ahead of 2024 Lok Sabha polls